Page 1

Schrödinger NEWS RELEASE Schrödinger Reports First Quarter 2021 Financial Results and Provides Company Update 5/11/2021 First quarter total revenue of $ 32.1 million , up 23 percent year - over - year ; Software revenue of $ 26.3 million , up 11 percent year - over - year Expanded agreement with AstraZeneca ; New agreement with NVIDIA Development candidate selected for MALT1 inhibitor program ; Internal pipeline progressing with plans to submit up to three investigational new drug applications to the FDA in 2022 Company maintains full - year 2021 financial outlook NEW YORK -- ( BUSINESS WIRE ) -- May 11 , 2021-- Schrödinger , Inc. ( Nasdaq : SDGR ) , whose physics - based software platform is transforming the way therapeutics and materials are discovered , today announced financial results for the quarter ended March 31 , 2021 , and provided an update on the company . " We had strong execution across multiple facets of our business during the quarter , " stated Ramy Farid , Ph.D. , chief executive officer at Schrödinger . " We are continuing to advance our internal drug discovery pipeline and recently selected a development candidate for our MALT1 inhibitor program . Progress on our internal programs , coupled with our collaborators ' successes with molecules we've helped discover , are powerful examples that our platform and approach generates high - quality development candidates . We look forward to seeing the full impact of our technology as pharmaceutical , biotechnology and materials companies adopt our platform on a larger scale . " Today the company announced an expanded collaboration with AstraZeneca to deploy Schrödinger's computational platform to help accelerate drug discovery . The collaboration is an expansion of the agreement 1